Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

A comparison of an anti-CD25 immunotoxin, Ontak and anti-CD25 microbeads for their ability to deplete alloreactive T cells in vitro

Bone Marrow Transplantation volume 37, pages 559–567 (2006)Cite this article

Abstract

Ex vivo depletion of alloreactive CD25+ T cells from a stem cell transplant (SCT) can reduce the incidence of graft-versus-host disease (GVHD) while preserving antimicrobial and perhaps antileukemia activity. However, the most effective methods for allodepleting T cells prior to transplant have not been determined. In this study, we have compared three agents that deplete CD25+ activated, alloreactive T cells. These included Ontak (Denileukin Diftitox), an IL-2 fusion toxin, anti-CD25 microbeads (MACS), an anti-CD25 immunotoxin (IT) and a combination of the IT and MACS. Peripheral blood mononuclear cells (PBMCs) activated in a primary mixed lymphocyte reaction (MLR) were allodepleted using optimal amounts of each agent, and the cells were then analyzed by flow cytometry. The treated cells were examined both for remaining alloreactivity and for the preservation of third party reactivity by testing them in a secondary MLR. Our data demonstrate that both the anti-CD25 IT and the anti-CD25 MACS were equally effective in depleting CD4+CD25+ cells and in sparing T cells that were reactive with third party cells. The anti-CD25 IT was, however, superior in depleting alloreactive CD8+CD25+ cells. In contrast, Ontak did not eliminate alloreactive cells and the Ontak-treated cells retained significant reactivity against the original stimulator cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Ferrara JLM, Deeg HJ . Graft-versus-host disease. N Engl J Med 1991; 324: 667–674.

    Article  CAS  Google Scholar 

  2. Murphy WJ, Blazar B . New strategies for preventing graft-versus-host disease. Curr Opin Immunol 1999; 11: 509–515.

    Article  CAS  Google Scholar 

  3. Przepiorka D, Ippoliti C, Koberda J, Chan KW, Khouri IF, Fisher HE et al. Interleukin-2 for prevention of graft-versus-host disease after haploidentical marrow transplantation. Transplantation 1994; 58: 858–860.

    Article  CAS  Google Scholar 

  4. Ferrara JL, Cooke KR, Teshima T . The pathophysiology of acute graft-versus-host disease. Int J Hematol 2003; 78: 181–187.

    Article  CAS  Google Scholar 

  5. Ho VT, Soiffer RJ . The history and future of T cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001; 98: 3192–3204.

    Article  CAS  Google Scholar 

  6. O'Reilly RJ, Collins N, Dinsmore R, Kernan N, Siena S, Brochstein J et al. Transplantation of HLA-mismatched marrow depleted of T cells by lectin agglutination and E-rosette depletion. Tokai J Exp Clin Med 1985; 10: 99–107.

    CAS  PubMed  Google Scholar 

  7. Michalek J, Collins RH, Vitetta ES . Clinical-scale selective depletion of alloreactive T cells using an anti-CD25 immunotoxin. Neoplasia 2003; 50: 296–299.

    CAS  Google Scholar 

  8. Solomon SR, Tran T, Carter CS, Donelly S, Hensel N, Schindler J et al. Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GVHD prophylaxis in allogeneic peripheral blood stem cell transplantation. Cytotherapy 2002; 4: 395–406.

    Article  CAS  Google Scholar 

  9. Solomon SR, Mielke S, Savani BN, Montero A, Wisch L, Childs R et al. Selective depletion of alloreactive donor lymphocytes – a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005; 106: 1123–1129.

    Article  CAS  Google Scholar 

  10. Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, Vitetta E, Schindler J, Chedeville G et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 2002; 360: 130–137.

    Article  Google Scholar 

  11. Amrolia P, Mucioli-Casadei G, Yvon E, Huls H, Sili U, Wieder D et al. Selective depletion of alloreactive T cells without loss of anti-viral or anti-leukemic responses. Blood 2004; 104: 1605 (Erratum).

    Article  CAS  Google Scholar 

  12. Amrolia PJ, Mucioli-Casadei G, Huls H, Gotsolva T, Durett A, Weiss H et al. Adaptive immunotherapy with allodepleted donor T cells improves immune reconstruction after haploidentical stem cell transplant. 2005, submitted.

  13. Eklund JW, Kuzel TM . Denileukin diftitox: a concise clinical review. Expert Rev Anticancer Ther 2005; 5: 33–38.

    Article  CAS  Google Scholar 

  14. Jansen J, Hanks S, Akard LP, Thompson JM, Burns S, Chang Q et al. Immunomagnetic CD4+ and CD8+ cell depletion for patients at high risk for severe acute GVHD. Bone Marrow Transplant 1996; 17: 377–382.

    CAS  PubMed  Google Scholar 

  15. Herrera CS, Torres A, Garcia-Castellano JM, Roman J, Martin C, Serrano J et al. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft. Bone Marrow Transplant 1999; 5: 443–450.

    Article  Google Scholar 

  16. Garderet L, Snell V, Przepiorka D, Schenk T, Lu JG, Marini F et al. Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. Transplantation 1999; 61: 124–130.

    Article  Google Scholar 

  17. Fehse B, Goldmann M, Frerk O, Bulduk M, Zander AR . Depletion of alloreactive donor T cells using immunomagnetic cell selection. Bone Marrow Transplant Suppl 2000; 2: S39–S42.

    Article  Google Scholar 

  18. Williams DP, Parker K, Bacha P, Bishai W, Borowski M, Genbauffe F et al. Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng 1987; 1: 493–498.

    Article  CAS  Google Scholar 

  19. Re GG, Waters C, Poisson L, Willingham MC, Sugamura K, Frankel AE . Interleukin 2 (IL-2) receptor expression and sensitivity to diptheria fusion toxin DAB389IL-2 in cultured hematopoietic cells. Cancer Res 1996; 56: 2590–2595.

    CAS  PubMed  Google Scholar 

  20. Ghetie V, Thorpe P, Ghetie MA, Knowles P, Uhr JW, Vitetta ES . The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond. J Immunol Methods 1991; 142: 223–230.

    Article  CAS  Google Scholar 

  21. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH . Identification and functional characterization of human CD4+ CD25+ T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193: 1285–1294.

    Article  CAS  Google Scholar 

  22. Bousvaros A, Stevens AC, Strom TB, Murphy J, Lamont JT . Interleukin-2 fusion protein (DAB389IL-2) selectively targets activated human peripheral blood and lamina propria lymphocytes. Dig Dis Sci 1997; 42: 1542–1548.

    Article  CAS  Google Scholar 

  23. Shao RH, Tian X, Gorgun G, Urbano AG, Foss FM . Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene. Leuk Res 2002; 26: 1077–1083.

    Article  CAS  Google Scholar 

  24. Michalek J, Collins RH, Durrani HP, Vaclakova P, Ruff LE, Douek DC et al. Definitive separation of graft-versus-leukemia-and graft-versus-host-specific CD4+ T cells by virtue of their receptor β loci sequences. Proc Natl Acad Sci USA 2003; 100: 1180–1184.

    Article  CAS  Google Scholar 

  25. Barrett AJ, Malkovaska V . Graft-versus-leukaemia: understanding and using the alloimmune response to treat haematological malignancies. Br J Haematol 1996; 93: 754–761.

    Article  CAS  Google Scholar 

  26. Zeiser R, Marks R, Bertz H, Finke J . Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies. Ann Hematol 2004; 83: 551–565.

    Article  CAS  Google Scholar 

  27. Barrett AJ, Mavroudis D, Tisdale J, Molldrem J, Clave E, Dunbar C et al. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant 1998; 21: 543–551.

    Article  CAS  Google Scholar 

  28. Cavazzana-Calvo M . Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin. Transplantation 1990; 50: 1–7.

    Article  CAS  Google Scholar 

  29. Ho VT, Zahrieh D, Hochberg E, Micale E, Levin J, Reynolds C et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 1224–1226.

    Article  CAS  Google Scholar 

  30. Shaughnessy PJ, Bachier C, Grimley M, Freytes CO, Callander NS, Essell JH et al. Denileukin diftitox for treatment of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 188–193.

    Article  CAS  Google Scholar 

  31. Oluwole SF, Oluwole OO, DePaz HA, Adeyeri AO, Witkowski P, Hardy MA . CD4+CD25+ regulatory T cells mediate acquired transplant tolerance. Transpl Immunol 2003; 11: 287–293.

    Article  CAS  Google Scholar 

  32. BaecherAllen C, Brown JA, Freeman GJ, Hafler DA . CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001; 167: 1245–1253.

    Article  Google Scholar 

  33. Sakaguchi S . Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 531–562.

    Article  CAS  Google Scholar 

  34. Koenen HJ, Fasse E, Joosten I . CD27/CFSE-based ex vivo selection of highly suppressive alloantigen-specific human regulatory T cells. J Immunol 2005; 174: 7573–7583.

    Article  CAS  Google Scholar 

  35. Mielke S, Rezvani K, Soloman SR, Kilical Y, Savani BN, Wisch L et al. Reconstitution of regulatory T cells after selective depletion of CD25+ host-reactive donor lymphocytes from allografts and association with acute graft-versus-host-disease (ASH abstract), 2005, in press.

Download references

Acknowledgements

We thank Ms Erica Garza and Ms Linda Berry for assistance in preparing the manuscript, Dr Victor Ghetie for preparing the immunotoxin, Ms Lien Le for providing us with the immunotoxin and antibodies, Drs Laurentiu Pop and Xiaoyun Liu for their technical advice; and Drs Nitin Karandikar, Radu Marches and Mr Paul Denton for reviewing of the manuscript.

Author information

Author notes

  1. P Vaclavkova and Y Cao: These authors contributed equally to this work.

  2. L K Wu: Studies were carried out in partial fulfillment of a doctoral degree in immunology

Authors and Affiliations

  1. The Cancer Immunobiology Center, University of Texas Southwestern Medical Center, Dallas, TX, USA

    P Vaclavkova, Y Cao, L K Wu, J Michalek & E S Vitetta

Authors
  1. P Vaclavkova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L K Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Michalek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E S Vitetta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E S Vitetta.

Additional information

This work was supported by a grant from Lymphoma and Leukemia Society and by the Cancer Immunobiology Center.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vaclavkova, P., Cao, Y., Wu, L. et al. A comparison of an anti-CD25 immunotoxin, Ontak and anti-CD25 microbeads for their ability to deplete alloreactive T cells in vitro. Bone Marrow Transplant 37, 559–567 (2006). https://doi.org/10.1038/sj.bmt.1705286

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705286

Keywords

Search

Advanced search

Quick links